Qualigen Therapeutics (QLGN) News Today $0.10 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Qualigen Therapeutics Announces 1-for-50 Reverse Stock SplitNovember 1 at 9:03 PM | markets.businessinsider.comShares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024November 1 at 9:00 AM | globenewswire.comQualigen Therapeutics, Inc. Announces management changes.September 26, 2024 | globenewswire.comQualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings PanelSeptember 20, 2024 | globenewswire.comUnivest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)September 6, 2024 | globenewswire.comQualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public OfferingSeptember 6, 2024 | globenewswire.comQualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public OfferingSeptember 5, 2024 | globenewswire.comQLGN Stock Earnings: Qualigen Therapeutics Reported Results for Q2 2024August 16, 2024 | investorplace.comWhy Is Qualigen Therapeutics (QLGN) Stock Down 22% Today?July 15, 2024 | investorplace.comWhy Is Qualigen (QLGN) Stock Up 141% Today?July 12, 2024 | investorplace.comWhy Is Qualigen Therapeutics (QLGN) Stock Down 12% Today?July 8, 2024 | investorplace.comWhy Is Qualigen Therapeutics (QLGN) Stock Down 12% Today?July 8, 2024 | investorplace.comQLGN Stock Earnings: Qualigen Therapeutics Reported Results for Q1 2024July 2, 2024 | investorplace.comQLGN Stock Earnings: Qualigen Therapeutics Beats EPS for Q4 2023June 3, 2024 | investorplace.comQualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting DeterminationMay 30, 2024 | globenewswire.comQualigen Announced An Agreement With Marizyme To Commercialize DuraGraftApril 16, 2024 | markets.businessinsider.comMarizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™April 16, 2024 | finance.yahoo.comQualigen presents preclinical novel cancer inhibitors at AACR 2024April 12, 2024 | uk.investing.comQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingApril 10, 2024 | globenewswire.comQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingApril 9, 2024 | globenewswire.comQualigen Therapeutics Inc Ordinary Shares QLGNFebruary 22, 2024 | morningstar.comQualigen Therapeutics Inc (QLGN)February 7, 2024 | uk.investing.comQLGN: Dosing Begins in Phase 1 Trial of QN-302…November 27, 2023 | finance.yahoo.comQualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023November 14, 2023 | finance.yahoo.comQualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNovember 7, 2023 | finance.yahoo.comPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerOctober 23, 2023 | finance.yahoo.comQualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023September 27, 2023 | finance.yahoo.comQualigen Therapeutics Inc (7R9.DU)September 2, 2023 | ca.finance.yahoo.comQLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23…August 30, 2023 | finance.yahoo.comQualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsAugust 17, 2023 | finance.yahoo.comQualigen Therapeutics GAAP EPS of -$0.69, revenue of $1.62MAugust 15, 2023 | msn.comQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023August 15, 2023 | finance.yahoo.comQualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsAugust 1, 2023 | finance.yahoo.comQualigen Therapeutics Divests FastPack® Diagnostics BusinessJuly 24, 2023 | finance.yahoo.comQLGN: Data for Pan-RAS Platform Presented at ASCO…June 14, 2023 | finance.yahoo.comPoster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJune 6, 2023 | technews.tmcnet.comPoster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingJune 5, 2023 | finance.yahoo.comQualigen Therapeutics GAAP EPS of -$0.78, revenue of $1.61MMay 18, 2023 | seekingalpha.comQualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023May 16, 2023 | finance.yahoo.comQLGN: IND for QN-302 to be Submitted in Mid-2023…May 12, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate UpdateMay 2, 2023 | finance.yahoo.comQualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual MeetingMay 2, 2023 | finance.yahoo.comQualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K FilingApril 21, 2023 | finance.yahoo.comQualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FLApril 18, 2023 | finance.yahoo.comQualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FLApril 18, 2023 | finance.yahoo.comQualigen Therapeutics, Inc.: Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark OfficeMarch 21, 2023 | finanznachrichten.deComposition of Matter Patent for QN-302 Granted by United States Patent and Trademark OfficeMarch 21, 2023 | finance.yahoo.comQualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023March 15, 2023 | finance.yahoo.comQualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS ConferenceMarch 9, 2023 | finance.yahoo.comData on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal MoleculesMarch 8, 2023 | finance.yahoo.com Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here QLGN Media Mentions By Week QLGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QLGN News Sentiment▼-0.530.43▲Average Medical News Sentiment QLGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QLGN Articles This Week▼30▲QLGN Articles Average Week Get Qualigen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GNPX News Today XCUR News Today HEPA News Today MYMD News Today CHRO News Today KTTA News Today CPHI News Today ARTL News Today PCSA News Today SHPH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QLGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Qualigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Qualigen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
